US Stem Cell Inc USRM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $64,150.73
- Volume/Avg
- 499,006 / 175,384
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 11
- Website
- http://www.us-stemcell.com
Valuation
|
Metric
|
USRM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
USRM
Financial Strength
|
Metric
|
USRM
|
|---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.00 |
Interest Coverage | −3.14 |
Quick Ratio
USRM
Profitability
|
Metric
|
USRM
|
|---|---|
Return on Assets (Normalized) | −2,007.84% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
USRM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xwqsqpcybf | Kyvk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nncyhftx | Vmyxksj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zjnwrrdbs | Sbkmqh | $97.8 Bil | |
MRNA
| Moderna Inc | Kryyqtx | Bcl | $38.8 Bil | |
ARGX
| argenx SE ADR | Hnxlljj | Lzr | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Jjxhccc | Kbrd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qsmftwy | Ykztsk | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tzjqxdvyt | Xbhqz | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ccvylblspg | Pntgj | $12.5 Bil | |
INCY
| Incyte Corp | Kvsrjylvf | Sxjxjfn | $11.5 Bil |